List of Excipients in Branded Drug BRIVARACETAM ORAL SOLUTION

Generic Drugs Containing BRIVARACETAM ORAL SOLUTION

Company	Ingredient	NDC	Excipient
Ascend Laboratories LLC	brivaracetam	67877-904	ANHYDROUS CITRIC ACID
Ascend Laboratories LLC	brivaracetam	67877-904	CARBOXYMETHYLCELLULOSE SODIUM
Ascend Laboratories LLC	brivaracetam	67877-904	GLYCERIN
Ascend Laboratories LLC	brivaracetam	67877-904	METHYLPARABEN
Ascend Laboratories LLC	brivaracetam	67877-904	NONCRYSTALLIZING SORBITOL SOLUTION
Ascend Laboratories LLC	brivaracetam	67877-904	SUCRALOSE
Ascend Laboratories LLC	brivaracetam	67877-904	TRISODIUM CITRATE DIHYDRATE

What are the Most Frequently-Used Excipients in BRIVARACETAM ORAL SOLUTION?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
2	CARBOXYMETHYLCELLULOSE SODIUM
2	GLYCERIN
1	METHYLPARABEN
1	METHYLPARABEN SODIUM
1	NONCRYSTALLIZING SORBITOL SOLUTION
1	SODIUM CITRATE

Brivaracetam Oral Solution Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Brivaracetam oral solution is a high-concentration, immediate-release antiepileptic formulation used when patients cannot swallow tablets or require flexible weight-based dosing. The commercial opportunity is concentrated in generic 10 mg/mL oral solution, pediatric and dysphagia markets, preservative and sugar-free reformulations, and differentiated packaging rather than in a novel active pharmaceutical ingredient.

The reference product, Briviact oral solution, contains brivaracetam at 10 mg/mL. Its publicly disclosed excipient system uses citrate buffering, methylparaben preservation, sucralose sweetening, flavoring, and purified water. That formulation creates a relatively accessible development target for an ANDA applicant, but taste, preservative performance, dose uniformity, and device compatibility remain practical barriers.

What excipients are used in brivaracetam oral solution?

The U.S. reference formulation contains the following inactive ingredients:

Component	Function
Sodium citrate dihydrate	Buffering agent and pH control
Citric acid, anhydrous	Acidifying agent and citrate-buffer component
Methylparaben	Antimicrobial preservative
Sucralose	High-intensity sweetener
Flavor	Palatability and taste masking
Purified water	Vehicle

The formulation is an aqueous, immediate-release solution at 10 mg/mL. The FDA label identifies the product as a clear, colorless to slightly yellow oral solution supplied in a bottle with a calibrated oral syringe.[1]

Why the excipient system is commercially relevant

Brivaracetam has a bitter drug substance profile typical of many central nervous system compounds. The reference formulation addresses this through acidification, high-intensity sweetening, flavoring, and preservative protection. A generic manufacturer does not need to reproduce every inactive ingredient, but it must produce a pharmaceutically equivalent product with acceptable stability, quality, and bioequivalence.

The formulation is relatively simple compared with a suspension. That reduces sedimentation, redispersion, particle-size, and dose-uniformity risks. The main technical challenge is organoleptic performance. A product that is chemically equivalent but poorly tolerated by children or patients with long-term use needs may lose share despite regulatory approval.

How does the brivaracetam oral solution formulation work?

The excipient strategy has four core functions:

1. Maintain chemical stability in an aqueous environment.
2. Control microbial growth after bottle opening.
3. Mask bitterness and acidic taste.
4. Deliver reproducible doses through an oral syringe.

Citrate buffer

The citric acid and sodium citrate combination controls formulation pH. A mildly acidic formulation can support chemical stability and improve preservative effectiveness. The buffer also helps maintain consistent product performance during the shelf life.

The buffer concentration must be controlled. Excessive buffering can produce an overly acidic taste, while insufficient capacity can allow pH drift caused by packaging interaction, water quality, carbon dioxide absorption, or repeated patient use.

Methylparaben

Methylparaben provides antimicrobial protection in a multidose bottle. Its concentration, solubility, and compatibility with the flavor system require evaluation during development.

Methylparaben can create commercial constraints in pediatric positioning because some prescribers and caregivers prefer preservative-free products. A preservative-free presentation would require a different container-closure and microbiological control strategy, such as unit-dose packaging or a validated antimicrobial packaging system.

Sucralose and flavor

Sucralose supplies sweetness without adding a substantial sugar load. It is compatible with sugar-free positioning and is widely used in pediatric liquids. Flavor selection is more difficult. The flavor must mask bitterness without producing an unpleasant aftertaste when combined with an acidic citrate system.

Potential alternatives include:

• Sucralose with fruit flavors.
• Acesulfame potassium or steviol glycosides.
• Polyols such as sorbitol or glycerol, subject to gastrointestinal tolerability.
• Ion-exchange or cyclodextrin taste-masking systems.
• Multiparticulate or coated drug delivery approaches.

A reformulation that removes methylparaben or improves taste could support premium or institutional positioning, but it would require new stability, microbial, and palatability data.

What regulatory pathway applies to generic brivaracetam oral solution?

A generic brivaracetam oral solution would normally be submitted through the FDA abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The principal regulatory requirements are:

Requirement	Relevance
Same active ingredient	Brivaracetam
Same dosage form	Oral solution
Same route	Oral
Same strength	10 mg/mL, unless otherwise supported
Pharmaceutical equivalence	Matching dosage form, strength, quality, and performance
Bioequivalence	Pharmacokinetic comparison to the reference listed drug
Stability	Accelerated and long-term data
Microbial quality	Limits and preservative-effectiveness data
Device compatibility	Oral syringe and bottle performance
Labeling	Generally consistent with the reference labeling

For a true solution, bioequivalence may be more straightforward than for a suspension because the active ingredient is already dissolved. The applicant must still demonstrate that excipients do not materially alter absorption. Differences in pH, viscosity, osmolality, sweeteners, or complexing agents can affect tolerability and, in some cases, drug exposure.

What patent and exclusivity issues affect brivaracetam oral solution?

Brivaracetam is a small-molecule drug, so biosimilar pathways do not apply. Generic applicants face patent and regulatory exclusivity analysis rather than biologic interchangeability issues.

FDA exclusivity timeline

Briviact received FDA approval in 2016. The five-year new chemical entity exclusivity period therefore expired in 2021, subject to the effect of any applicable pediatric extension. Pediatric exclusivity can add six months to qualifying exclusivity and patent rights under the FDA pediatric framework.[1][2]

The principal market-access questions are now patent-related:

• Whether listed patents remain enforceable.
• Whether any formulation or method-of-use patents cover the proposed product.
• Whether the applicant can file a Paragraph IV certification.
• Whether the reference sponsor files patent litigation within the statutory period.
• Whether a 30-month stay applies.
• Whether the applicant secures a first-filer or other market-entry advantage.

Orange Book status

Briviact is an NDA product listed in the FDA Orange Book. Orange Book analysis should separate:

• Active-ingredient patents.
• Formulation patents.
• Method-of-use patents.
• Patents that may be irrelevant to an oral-solution ANDA.
• Patent listings with expiration dates extending beyond regulatory exclusivity.

The key legal distinction is between patents that claim brivaracetam broadly and patents that claim a specific liquid formulation. A generic oral solution can sometimes avoid a formulation patent by using materially different excipients, pH, preservative systems, or packaging, provided the product remains pharmaceutically acceptable and bioequivalent.

Paragraph IV challenge risk

A Paragraph IV filing is the main route for an early generic challenge to an unexpired listed patent. The commercial value of a challenge depends on:

• The remaining patent term.
• The breadth of the claims.
• Prosecution history and disclaimer issues.
• Whether the claim requires a specific excipient combination.
• Whether the claim covers only a method of treating a particular patient population.
• The likelihood of a 30-month stay.
• The probability of settlement or launch at risk.

A composition-of-matter patent covering brivaracetam itself presents a higher barrier than a narrow liquid formulation patent. A formulation patent based on citrate, methylparaben, sucralose, and flavor may be vulnerable if the claims are narrow and the generic uses a different preservative or taste-masking system.

What formulation patents could protect a brivaracetam oral solution?

A commercially meaningful formulation patent could claim one or more of the following:

pH-controlled aqueous solutions

Claims may specify:

• Brivaracetam concentration.
• pH range.
• Citrate concentration.
• Buffer ratio.
• Long-term chemical stability.
• Low degradation-product levels.

These claims can be designed around if the generic formulation uses a different buffer, a different pH range, or a nonaqueous co-solvent system. The applicant must balance design-around freedom against taste and stability.

Preservative systems

A patent may claim methylparaben alone or in combination with other preservatives. Alternative systems could include potassium sorbate, sodium benzoate, benzyl alcohol, or preservative-free packaging. Each alternative creates separate pediatric safety, taste, and regulatory considerations.

Taste-masking systems

Potentially protectable approaches include:

• Complexation with cyclodextrins.
• Ion-exchange resins.
• Polymeric coating.
• Lipid-based microencapsulation.
• Sweetener and flavor combinations.
• pH-dependent taste suppression.

Taste-masking patents are commercially attractive because they can support product differentiation even after the active-ingredient patent expires.

Packaging and dosing systems

A product sponsor can also protect:

• Bottle and oral-syringe combinations.
• Child-resistant closure systems.
• Unit-dose ampoules.
• Dose counters.
• Low-residual-volume syringes.
• Packaging that reduces preservative exposure or microbial contamination.

Packaging claims may not block a conventional generic bottle, but they can protect premium presentations for pediatric, hospital, and home-care markets.

How strong is the patent estate for brivaracetam oral solution?

The patent estate should be viewed as layered rather than uniform.

Layer	Strategic strength	Relevance to oral solution
Brivaracetam composition of matter	High while in force	Can block all generic forms
Broad therapeutic-use claims	Medium	Depends on label and proposed indications
Specific oral-solution formulation	Medium to high if claims are narrow and validated	Directly relevant
Taste-masking formulation	Medium	Can support differentiated products
Packaging and dosing device	Low to medium	Usually avoidable
Manufacturing process	Medium	Relevant if process claims are broad
Trade-secret know-how	Medium	Can delay development without creating an automatic market block

The most important commercial question is whether the remaining enforceable claims cover the active ingredient itself or only the branded formulation. If active-ingredient protection has expired, excipient design-around becomes a central generic strategy.

What commercial opportunities exist for brivaracetam oral solution?

Generic 10 mg/mL oral solution

The clearest opportunity is a conventional ANDA product closely matching the reference formulation. The product can compete on:

• Wholesale acquisition cost.
• Medicaid and managed-care reimbursement.
• Supply reliability.
• Bottle and syringe configuration.
• Pharmacy distribution.
• Contract manufacturing economics.

The solution format may have lower manufacturing complexity than tablets because it avoids compression, coating, and solid-state controls. It has higher packaging, microbial, and shipping requirements.

Pediatric formulation positioning

Brivaracetam is used in pediatric patients, and oral solution is particularly relevant where tablets are unsuitable. Commercial differentiation can focus on:

• Improved flavor.
• Lower aftertaste.
• Small-volume dosing.
• Clear dose graduations.
• Low-sugar or sugar-free labeling.
• Reduced dosing error.
• Unit-dose formats for hospitals and schools.

Pediatric claims cannot be inferred solely from commercial positioning. They must align with the approved label and supporting clinical or regulatory data.

Hospital and institutional packaging

Hospitals may prefer unit-dose presentations that reduce contamination risk and simplify medication administration. Potential formats include:

• Single-use oral syringes.
• Unit-dose cups.
• Small-volume bottles.
• Tamper-evident packaging.
• Barcoded packaging compatible with automated medication administration.

These formats can command a higher net price but increase filling, packaging, and stability costs.

Preservative-free product

A preservative-free version could target patients with preservative sensitivity or caregivers seeking a lower-excipient product. The most viable format is likely unit-dose packaging rather than a conventional multidose bottle.

The commercial tradeoff is direct: preservative-free products can improve positioning but require higher packaging costs, more inventory units, and stronger control of aseptic or microbiological risks.

Specialty pharmacy and adherence programs

Brivaracetam oral solution can support adherence programs for patients with swallowing limitations, developmental disabilities, neurological disease, or complex medication regimens. Commercial services may include dose-specific packaging and syringe replacement, although reimbursement for these services varies by payer and channel.

How does brivaracetam oral solution compare with competing antiepileptic liquids?

Product	Active ingredient	Typical liquid positioning	Competitive implication
Briviact oral solution	Brivaracetam	10 mg/mL	Branded reference and generic target
Keppra oral solution	Levetiracetam	Established pediatric and generic liquid	Strong price and familiarity competition
Vimpat oral solution	Lacosamide	Pediatric and swallowing-limited patients	Competes in focal-onset epilepsy
Depakene oral solution	Valproic acid	Broad antiseizure use	Different safety and tolerability profile
Fycompa oral suspension	Perampanel	Oral suspension with distinct dosing profile	Alternative liquid CNS product

Levetiracetam is the most important commercial comparator because it has broad generic availability and established pediatric use. Brivaracetam can differentiate through pharmacology, prescribing preference, tolerability, and supply rather than through an unusually complex liquid formulation.

What manufacturing and IP barriers affect market entry?

The primary barriers are technical execution and patent timing.

Manufacturing barriers

A manufacturer must control:

• Brivaracetam assay and degradation products.
• Homogeneity throughout filling.
• Preservative concentration.
• Microbial limits.
• pH drift.
• Flavor uniformity.
• Container adsorption or leachables.
• Oral-syringe dose accuracy.
• Freeze-thaw and transport stability.
• In-use stability after opening.

The product is less technically complex than a suspension, but small deviations in taste, pH, or preservative performance can affect patient acceptance and regulatory review.

Intellectual-property barriers

The main IP risks are:

• Broad brivaracetam compound claims.
• Liquid formulation claims.
• Use claims tied to epilepsy or seizure types.
• Manufacturing-process claims.
• Packaging claims.
• Hatch-Waxman litigation following a Paragraph IV filing.

A design-around strategy should be developed before ANDA filing. It should evaluate alternative buffers, preservative systems, sweeteners, flavors, and container formats while maintaining equivalent performance.

What is the likely generic launch scenario?

The most likely entry sequence is:

1. A conventional 10 mg/mL oral-solution ANDA.
2. A Paragraph IV certification against any remaining relevant listed patents.
3. Litigation or a negotiated settlement.
4. Launch on the earliest legally available date.
5. Price competition after one or more approvals.
6. Subsequent differentiation through preservative-free, unit-dose, or taste-optimized formats.

The first approved generic may obtain a temporary commercial advantage if it is the only competitor. That advantage is usually strongest in formularies and pharmacy contracts, then declines as additional suppliers enter.

Key Takeaways

• Brivaracetam oral solution uses a relatively simple aqueous excipient platform: citrate buffer, methylparaben, sucralose, flavor, and purified water.
• The strongest product opportunity is a generic 10 mg/mL solution supported by reliable supply and competitive pricing.
• The main formulation development risk is taste, not dissolution or suspension uniformity.
• Preservative-free, unit-dose, and taste-optimized versions offer the clearest differentiated opportunities.
• A small-molecule generic pathway applies; biosimilar development is irrelevant.
• Patent risk depends on whether enforceable claims cover brivaracetam broadly or only specific liquid formulations.
• Orange Book and Paragraph IV analysis should focus on active-ingredient, formulation, method-of-use, and packaging claims separately.
• Levetiracetam oral solution is the principal commercial comparator because it has a mature generic market and broad clinical familiarity.

FAQs

Is brivaracetam oral solution sugar-free?

The reference formulation uses sucralose rather than sucrose as its disclosed sweetener. This supports a sugar-free positioning, subject to the complete product labeling.

Can a generic brivaracetam oral solution use different excipients?

Yes. An ANDA product does not necessarily need to copy every inactive ingredient, but excipient differences must not affect safety, stability, bioequivalence, or product performance.

Is methylparaben necessary in brivaracetam oral solution?

Methylparaben is used in the reference multidose formulation for antimicrobial preservation. A generic may pursue another preservative system or preservative-free unit-dose packaging if it can satisfy microbiological and stability requirements.

Does brivaracetam oral solution have biosimilar competition?

No. Brivaracetam is a small-molecule drug. Competition proceeds through generic drug applications, not biosimilar applications.

What is the best commercial formulation opportunity after generic entry?

A taste-optimized, preservative-free or unit-dose oral solution has the strongest potential for differentiation, especially in pediatric, hospital, and swallowing-impaired patient populations.

References

1. U.S. Food and Drug Administration. (2024). Briviact (brivaracetam) prescribing information. UCB, Inc.

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.